Maxim lowered the firm’s price target on Lineage Cell Therapeutics (LCTX) to $3 from $5 and keeps a Buy rating on the shares. Sana Biotechnology (SANA), another player in the cell transplant ...
Sana’s HIP technology aims to eliminate the ... In the past 30 days, estimates for CytomX Therapeutics’ 2024 loss per share have remained constant at 5 cents. Estimates for 2025 loss per ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback